190 related articles for article (PubMed ID: 23518212)
21. Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study.
Lévy S; Hartikainen J; Ritz B; Juhlin T; Carbajosa-Dalmau J; Domanovits H
Cardiovasc Drugs Ther; 2021 Apr; 35(2):283-292. PubMed ID: 33206300
[TBL] [Abstract][Full Text] [Related]
22. Vernakalant hydrochloride: A novel atrial-selective agent for the cardioversion of recent-onset atrial fibrillation in the emergency department.
Stiell IG; Dickinson G; Butterfield NN; Clement CM; Perry JJ; Vaillancourt C; Calder LA
Acad Emerg Med; 2010 Nov; 17(11):1175-82. PubMed ID: 21175515
[TBL] [Abstract][Full Text] [Related]
23. Vernakalant in the management of atrial fibrillation.
Cheng JW
Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
[TBL] [Abstract][Full Text] [Related]
24. Vernakalant: A novel agent for the termination of atrial fibrillation.
Finnin M
Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
Akel T; Lafferty J
Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
[TBL] [Abstract][Full Text] [Related]
26. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
Duggan ST; Scott LJ
Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
[TBL] [Abstract][Full Text] [Related]
27. Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.
Bash LD; Buono JL; Davies GM; Martin A; Fahrbach K; Phatak H; Avetisyan R; Mwamburi M
Cardiovasc Drugs Ther; 2012 Apr; 26(2):167-79. PubMed ID: 22418856
[TBL] [Abstract][Full Text] [Related]
28. [Vernakalant: a novel antiarrhythmic drug for the rapid conversion of atrial fibrillation to sinus rhythm].
Hirt MN; Eschenhagen T
Dtsch Med Wochenschr; 2010 May; 135(19):971-6. PubMed ID: 20446233
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
[TBL] [Abstract][Full Text] [Related]
30. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial.
Kowey PR; Dorian P; Mitchell LB; Pratt CM; Roy D; Schwartz PJ; Sadowski J; Sobczyk D; Bochenek A; Toft E;
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):652-9. PubMed ID: 19948506
[TBL] [Abstract][Full Text] [Related]
31. Vernakalant: conversion of atrial fibrillation in patients with ischemic heart disease.
Torp-Pedersen C; Camm AJ; Butterfield NN; Dickinson G; Beatch GN
Int J Cardiol; 2013 Jun; 166(1):147-51. PubMed ID: 22108512
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
Dominijanni G; Caballero-Bermejo AF; Martín Jiménez ML; Calpe Delgado P; Rodríguez-Miranda B; Ruiz-Antorán B
Emergencias; 2024 Jun; 36(3):239-240. PubMed ID: 38819000
[No Abstract] [Full Text] [Related]
33. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial.
Roy D; Pratt CM; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Nielsen T; Rasmussen SL; Stiell IG; Coutu B; Ip JH; Pritchett EL; Camm AJ;
Circulation; 2008 Mar; 117(12):1518-25. PubMed ID: 18332267
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
[TBL] [Abstract][Full Text] [Related]
35. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
Tian D; Frishman WH
Cardiol Rev; 2011; 19(1):41-4. PubMed ID: 21135602
[TBL] [Abstract][Full Text] [Related]
36. Implementing vernakalant: a novel approach to cardioversion.
Hall A
Emerg Nurse; 2018 Dec; 27(1):14-20. PubMed ID: 30550052
[TBL] [Abstract][Full Text] [Related]
37. [Vernakalant in hospital emergency practice: safety and effectiveness].
Carbajosa Dalmau J; Cosín-Sales J; Pérez-Durá MJ; Noceda J; Urtubia-Palacios A; Hernández-Sori N; Peiró-Gómez A; Jacob J; Llorens P; Ruescas-Gómez L; Martín-Martínez A
Emergencias; 2017 Dic; 29(6):397-402. PubMed ID: 29188914
[TBL] [Abstract][Full Text] [Related]
38. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
[TBL] [Abstract][Full Text] [Related]
39. Conversion of recent onset atrial fibrillation: which drug is faster?
Conde D
Am J Emerg Med; 2013 Sep; 31(9):1410-1. PubMed ID: 23796978
[No Abstract] [Full Text] [Related]
40. Vernakalant: RSD 1235, RSD-1235, RSD1235.
Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
